Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2013, Article ID 263287, 12 pages
http://dx.doi.org/10.1155/2013/263287
Research Article

Subthalamic hGAD65 Gene Therapy and Striatum TH Gene Transfer in a Parkinson’s Disease Rat Model

1Beijing Institute for Neuroscience, Beijing Center for Neural Regeneration & Repair, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Capital Medical University, Beijing 100069, China
2Department of Anatomy, Basic College, Liaoning Medical University, Jinzhou, Liaoning 121001, China
3Medical Center for Experiment and Testing, Capital Medical University, Beijing 100069, China

Received 17 December 2012; Revised 19 March 2013; Accepted 2 April 2013

Academic Editor: Michel Baudry

Copyright © 2013 Deyu Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Bencsics, S. R. Wachtel, S. Milstien, K. Hatakeyama, J. B. Becker, and U. J. Kang, “Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts,” Journal of Neuroscience, vol. 16, no. 14, pp. 4449–4456, 1996. View at Google Scholar · View at Scopus
  2. T. N. Chase, F. Baronti, G. Fabbrini, I. J. Heuser, J. L. Juncos, and M. M. Mouradian, “Rationale for continuous dopaminomimetic therapy of Parkinson's disease,” Neurology, vol. 39, no. 11, pp. 7–10, 1989. View at Google Scholar · View at Scopus
  3. T. Wichmann and J. O. Dostrovsky, “Pathological basal ganglia activity in movement disorders,” Neuroscience, vol. 198, pp. 232–244, 2011. View at Google Scholar
  4. J. M. Brotchie, J. Lee, and K. Venderova, “Levodopa-induced dyskinesia in Parkinson's disease,” Journal of Neural Transmission, vol. 112, no. 3, pp. 359–391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Bernheimer, W. Birkmayer, and O. Hornykiewicz, “Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations,” Journal of the Neurological Sciences, vol. 20, no. 4, pp. 415–455, 1973. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Fahn, “Levodopa in the treatment of Parkinson's disease,” Journal of Neural Transmission, no. 71, pp. 1–15, 2006. View at Google Scholar · View at Scopus
  7. L. J. Fisher, H. A. Jinnah, L. C. Kale, G. A. Higgins, and F. H. Gage, “Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa,” Neuron, vol. 6, no. 3, pp. 371–380, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. C. L. Duan, Y. Su, C. L. Zhao, L. L. Lu, Q. Y. Xu, and H. Yang, “The assays of activities and function of TH, AADC, and GCH1 and their potential use in ex vivo gene therapy of PD,” Brain Research Protocols, vol. 16, no. 1–3, pp. 37–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. I. Muramatsu, A. Kume, M. Matsumura et al., “Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes,” Human Gene Therapy, vol. 13, no. 3, pp. 345–354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Björklund, T. Björklund, and D. Kirik, “Gene therapy for dopamine replacement in Parkinson's disease,” Science Translational Medicine, vol. 1, no. 2, p. 2ps2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. During, J. R. Naegele, K. L. O'Malley, and A. I. Geller, “Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase,” Science, vol. 266, no. 5189, pp. 1399–1403, 1994. View at Google Scholar · View at Scopus
  12. O. Corti, A. Sánchez-Capelo, P. Colin, N. Hanoun, M. Hamon, and J. Mallet, “Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 21, pp. 12120–12125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Wolff, L. J. Fisher, L. Xu et al., “Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 22, pp. 9011–9014, 1989. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Lu, C. Zhao, Y. Liu et al., “Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease,” Brain Research Protocols, vol. 15, no. 1, pp. 46–51, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Forsayeth, J. L. Eberling, L. M. Sanftner et al., “A Dose-Ranging Study of AAV-hAADC therapy in Parkinsonian monkeys,” Molecular Therapy, vol. 14, no. 4, pp. 571–577, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sun, G. R. Zhang, L. Kong et al., “Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector,” Human Gene Therapy, vol. 14, no. 5, pp. 415–424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Sun, L. Kong, X. Wang et al., “Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease,” Human Gene Therapy, vol. 15, no. 12, pp. 1177–1196, 2004. View at Google Scholar · View at Scopus
  18. S. Bickel, L. Alvarez, R. Macias et al., “Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson's disease,” Parkinsonism and Related Disorders, vol. 16, no. 8, pp. 535–539, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. N. K. Patel, P. Heywood, K. O'Sullivan, R. McCarter, S. Love, and S. S. Gill, “Unilateral subthalamotomy in the treatment of Parkinson's disease,” Brain, vol. 126, no. 5, pp. 1136–1145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. H. M. Tseng, P. C. Su, H. M. Liu, H. H. Liou, and R. F. Yen, “Bilateral subthalamotomy for advanced Parkinson disease,” Surgical Neurology, vol. 68, supplement 1, pp. S43–S50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Luo, M. G. Kaplitt, H. L. Fitzsimons et al., “Subthalamic GAD gene therapy in a Parkinson's disease rat model,” Science, vol. 298, no. 5592, pp. 425–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Y. Mastakov, K. Baer, C. W. Symes, C. B. Leichtlein, R. M. Kotin, and M. J. During, “Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain,” Journal of Virology, vol. 76, no. 16, pp. 8446–8454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. U. Kim, I. H. Park, T. H. Kim et al., “Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease,” Neuropathology, vol. 26, no. 2, pp. 129–140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Singh, K. Singh, D. K. Patel et al., “The expression of cyp2d22, an ortholog of human cyp2d6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinson's disease phenotype and nicotine-mediated neuroprotection,” Rejuvenation Research, vol. 12, no. 3, pp. 185–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Melamed, F. Hefti, V. Bitton, and M. Globus, “Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism,” Neurology, vol. 34, no. 12, pp. 1566–1570, 1984. View at Google Scholar · View at Scopus
  26. M. G. Kaplitt, A. D. Kwong, S. P. Kleopoulos, C. V. Mobbs, S. D. Rabkin, and D. W. Pfaff, “Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 19, pp. 8979–8983, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Duan, H. Yang, J. Zhang, J. Zhang, and Q. Xu, “Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease,” Experimental Brain Research, vol. 161, no. 3, pp. 316–324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. During, K. M. Ryder, and D. D. Spencer, “Hippocampal GABA transporter function in temporal-lobe epilepsy,” Nature, vol. 376, no. 6536, pp. 174–177, 1995. View at Google Scholar · View at Scopus
  29. D. Young, P. A. Lawlor, P. Leone, M. Dragunow, and M. J. During, “Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective,” Nature Medicine, vol. 5, no. 4, pp. 448–453, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Martin and K. E. Barke, “Are GAD65 and GAD67 associated with specific pools of GABA in brain?” Perspectives on Developmental Neurobiology, vol. 5, no. 2-3, pp. 119–129, 1998. View at Google Scholar · View at Scopus
  31. K. G. Lloyd, H. Mohler, Heitz Ph., and G. Bartholini, “Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and parkinsonian patients,” Journal of Neurochemistry, vol. 25, no. 6, pp. 789–795, 1975. View at Google Scholar · View at Scopus
  32. M. G. Erlander, N. J. K. Tillakaratne, S. Feldblum, N. Patel, and A. J. Tobin, “Two genes encode distinct glutamate decarboxylases,” Neuron, vol. 7, no. 1, pp. 91–100, 1991. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Gaspar, F. Javoy-Agid, A. Ploska, and Y. Agid, “Regional distribution of neurotransmitter synthesizing enzymes in the basal ganglia of human brain,” Journal of Neurochemistry, vol. 34, no. 2, pp. 278–283, 1980. View at Google Scholar · View at Scopus
  34. V. Vialou, L. Balasse, S. Dumas, B. Giros, and S. Gautron, “Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain,” Neuroscience, vol. 144, no. 2, pp. 616–622, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. J. Kish, A. Rajput, and J. Gilbert, “Elevated γ-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss,” Annals of Neurology, vol. 20, no. 1, pp. 26–31, 1986. View at Google Scholar · View at Scopus
  36. J. J. Soghomonian and N. Laprade, “Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of Parkinsonian monkeys,” Synapse, vol. 27, pp. 122–132, 1997. View at Google Scholar
  37. N. Laprade and J. J. Soghomonian, “Glutamate decarboxylase (GAD65) gene expression is increased by dopamine receptor agonists in a subpopulation of rat striatal neurons,” Molecular Brain Research, vol. 48, no. 2, pp. 333–345, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. D. T. Stephenson, Q. Li, C. Simmons et al., “Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration,” Neurobiology of Disease, vol. 20, no. 2, pp. 347–359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. J. Soghomonian, S. Pedneault, G. Audet, and A. Parent, “Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates,” Journal of Neuroscience, vol. 14, no. 10, pp. 6256–6265, 1994. View at Google Scholar · View at Scopus
  40. J. M. Henderson, “Experimental therapeutics of Parkinson's disease,” Clinical and Experimental Pharmacology and Physiology, vol. 30, no. 11, pp. 841–844, 2003. View at Publisher · View at Google Scholar · View at Scopus